Abstract:The epidemiology of IFD following pediatric heart transplantation (pHT) is poorly characterized. We sought to evaluate use of antifungal prophylaxis and describe the epidemiology of IFD in pHT at two large children's hospitals. We performed a retrospective cohort study of pediatric and young adult (≤21 years) patients undergoing heart transplantation at Cincinnati Children's Hospital Medical Center (CCHMC) and Children's Hospital of Philadelphia (CHOP) between 2012 and 2021. We recorded demographic, clinical, medication, and laboratory data for pHT patients through 12 months post-transplant. We identified use of topical (oral nystatin) and systemic antifungal prophylaxes in the peri-transplant period (7 days prior through 14 days following transplant) and analyzed if certain transplant variables were associated with the administration of systemic antifungals during this period using rank sum and chi squared tests. Applying published definitions, we quantified the incidence of proven and probable IFD and explored the characteristics of these cases. A total of 201 patients underwent heart transplant at CCHMC and CHOP. The majority were male (60.2%), White (66.7%), and not Hispanic or Latino (88.1%). Median age at time of transplant was 7.4 years (IQR 0.9-14.2). During the peri-transplant period, 143 (71.1%) patients received oral nystatin and 37 (18.4%) received systemic antifungal prophylaxis, not including PJP prophylaxis. 41 individuals (20.4%) were not on any antifungal prophylaxis throughout this period. Delayed chest closure was significantly associated with the administration of systemic antifungals (p<0.001) while several other variables (age, hospital, immunosuppression medication, ECMO/LVAD pre-transplant) were not. In total, 8 patients (4%) developed proven (n=5) or probable (n=3) IFD. In our cohort, the incidence rate of proven/probable IFD in the first year post-transplant was 44.8 per 1000 patient-years. The characteristics of these cases are shown in Table 1. Time from pHT to IFD ranged from 11 days to 196 days (median time = 25.5 days). All cases of proven IFD occurred within 28 days of transplant. In three cases of proven/probable IFD, patients were receiving a systemic antifungal or PJP prophylaxis in the seven days prior to IFD onset. Two cases met the definition of probable IFD but the infections resolved without directed therapies. Four patients with proven IFD died within 1 year following transplant, although in only 3 cases was IFD a contributing factor. The one-year all-cause mortality rate among pHT patients with proven/probable IFD (50%) was higher than that in pHT patients without IFD (10.3%; Fisher's exact p=0.008). Over a 10-year period at CCHMC and CHOP, 4% of pHT patients developed proven or probable IFD within one-year post-transplant. All proven IFD cases occurred within a month of transplant while probable cases occurred more than 100 days post-transplant. Delayed chest closure was significantly associated with the administration of systemic antifungal prophylaxis. Patients with proven IFD had poor outcomes despite receipt of appropriate antifungal treatment. Given the low incidence of IFD at these two centers, we were unable to evaluate risk factors for IFD in this population and so larger studies would be needed. Table 1 Characteristics of patient with proven or probable invasive fungal disease Abbreviations: IFD, invasive fungal disease; NOS, not otherwise specified. Seen on microscopic examination of peritoneal fluid but did not grow on culture. Diagnosed on respiratory culture, with positive bronchoalveolar lavage cytology and imaging concerning for pulmonary fungal disease. Positive antigen testing in serum in the setting of pulmonary nodules. Positive PCR on sputum specimen in patient with pulmonary infiltrates. Patient died within one year of transplant but unrelated to IFD. Table 1 Characteristics of patient with proven or probable invasive fungal disease Abbreviations: IFD, invasive fungal disease; NOS, not otherwise specified. Seen on microscopic examination of peritoneal fluid but did not grow on culture. Diagnosed on respiratory culture, with positive bronchoalveolar lavage cytology and imaging concerning for pulmonary fungal disease. Positive antigen testing in serum in the setting of pulmonary nodules. Positive PCR on sputum specimen in patient with pulmonary infiltrates. Patient died within one year of transplant but unrelated to IFD.

Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients

Relationship Between Gene Polymorphism of Recipient/Donor Immune Pathway and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting

Invasive Fungal Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Single Center Experiences of 12 Years

Invasive Fungal Disease in Pediatric Heart Transplant Recipients

Risk Factors and Clinical Analysis for Invasive Fungal Infection in Neonatal Intensive Care Unit Patients

The Incidence and Risk Factors of Invasive Fungal Infection after Haploidentical Haematopoietic Stem Cell Transplantation Without in Vitro T-cell Depletion

[The Prevalence and Risk Factors of Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipients].

Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.

Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients

Risk factors for invasive fungal infections after hematopoietic stem cell transplantation: a systematic review and meta-analysis

A Retrospective Analysis of Micafungin Prophylaxis in Children Under 12 Years Undergoing Chemotherapy or Hematopoietic Stem Cell Transplantation

Timing Determination of Invasive Fungal Infection Prophylaxis According to Immune Function in HSCT Patients.

2714. Invasive Fungal Disease in Lung Transplant Recipients: Incidence, Risk Factors, and Outcomes

Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients

Antifungal Prophylaxis Utilization and the Associated Clinical Outcomes Among Pediatric Patients with Hematological Malignancies or Undergoing Hematopoietic Stem Cell Transplantation

Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study

Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.

Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study

A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes.